Compare FOA & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOA | STXS |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | 784 | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.8M | 182.3M |
| IPO Year | N/A | 2004 |
| Metric | FOA | STXS |
|---|---|---|
| Price | $19.90 | $1.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $26.00 | $4.00 |
| AVG Volume (30 Days) | 49.3K | ★ 364.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | $0.58 | $28.22 |
| Revenue Next Year | $6.91 | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.77 | $1.74 |
| 52 Week High | $29.58 | $3.59 |
| Indicator | FOA | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 46.53 |
| Support Level | $19.00 | $1.75 |
| Resistance Level | $23.63 | $1.99 |
| Average True Range (ATR) | 1.07 | 0.10 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 22.76 | 47.92 |
Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.